Emine Rabia KOÇ, Ertuğrul UZAR, Yasemin ÇIRAK, Yasemin Parlak DEMİR, Atilla İLHAN

The increase of mean platelet volume in patients with Alzheimer disease

Vascular risk factors play an important role in the progression of Alzheimer disease (AD). Mean platelet volume (MPV) is a determinant of platelet functionality and increased MPV is associated with an increased risk of vascular inflammation. Here we aimed to examine whether MPV could be used as a marker of vascular damage in AD and to discuss the relation between MPV and other vascular risk factors. Materials and methods: A total of 109 outpatients with AD and 81 healthy controls were included in this study. Diagnosis of AD was made according to defined criteria. The Turkish version of the Mini Mental State Examination (MMSE) was used for cognitive assessment. According to the test results, patients were divided into 2 subgroups, mild (MMSE => 18) and moderate (MMSE < 18), and their MPV levels were compared. Results: MPV levels were higher in the AD group. There was no statistically significant difference between the moderate group and the mild group according to MPV values. Conclusion: Increased MPV in patients with AD may point to platelet dysfunction. MPV is an indicator of increased in vivo platelet activation. Hence, platelets could be the link between vascular risk factors and AD. The assessment of MPV in patients with AD may help identify the patients that could benefit from additional antiplatelet therapy.

Anahtar Kelimeler:

Alzheimer disease, dementia, cognitive decline, mean platelet volume, platelet activation, vascular risk factors

The increase of mean platelet volume in patients with Alzheimer disease

Keywords:

Alzheimer disease, dementia, cognitive decline, mean platelet volume, platelet activation, vascular risk factors,

PDF

___

de la Torre JC. Vascular basis of Alzheimer’s pathogenesis. Ann N Y Acad Sci 2002; 977: 196–215.
Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, Di Luca M, Lenzi GL, Romanelli G, Caimi L et al. Microvascular damage and platelet abnormalities in early Alzheimer’s disease. J Neurol Sci 2002; 203–204: 189 –193.
Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997; 349: 151–154.
Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003; 9: 177–190.
Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378–3384.
Martin JF, Shaw T, Heggie J, Penington DG. Measurement of the density of human platelets and its relationship to volume. Br J Haematol 1983; 54: 337–352.
Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13: 301–306.
Bancroft AJ, Abel EW, McLaren M, Belch JJ. Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter thrombocytometer. Platelets 2000; 11: 379–387.
Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399–404.
Lancé MD, Sloep M, Henskens YM, Marcus MA. Mean platelet volume as a diagnostic marker for cardiovascular disease: drawbacks of preanalytical conditions and measuring techniques. Clin Appl Thromb Hemost 2012; 18: 561–568.
Köşüş N, Köşüş A, Turhan N. Mean platelet volume as a marker of future cardiovascular disease risk in pregnant women with impaired fasting glucose and impaired glucose tolerance. Turk J Med Sci 2012; 42: 245–251.
Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 2004; 35: 1688–1691.
Bath P, Algert C, Chapman N, Neal B. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622– 626.
Laske C, Sopova K, Stellos K. Platelet activation in Alzheimer’s disease: from pathophysiology to clinical value. Curr Vasc Pharmacol 2012; 10: 626–630.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.
Trull TJ, Vergés A, Wood PK, Jahng S, Sher KJ. The structure of Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision) personality disorder symptoms in a large national sample. Personal Disord 2012; 3: 355–369.
Güngen C, Ertan T, Eker E, Yaşar R, Engin F. Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population. Turk Psikiyatri Derg 2002; 13: 273–281 (article in Turkish with English abstract).
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
Arıkanoğlu A, Çevik MU, Uzar E, Acar A, Akıl E, Ekici F, Taşdemir N. The increase of the mean platelet volume in patients with intracerebral haemorrhage. Turkish Journal of Neurology 2012; 18: 54–56 (article in Turkish with English abstract).
Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab 2010; 30: 1817–1820.
Canan F, Dikici S, Kutlucan A, Celbek G, Coskun H, Gungor A, Aydin Y, Kocaman G. Association of mean platelet volume with DSM-IV major depression in a large community-based population: the MELEN study. J Psychiatr Res 2012; 46: 298– 302.
Claassen JA, Diaz-Arrastia R, Martin-Cook K, Levine BD, Zhang R. Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial Doppler. J Alzheimers Dis 2009; 17: 621–629.
Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 2010; 45: 53–56.
Yesil Y, Kuyumcu ME, Cankurtaran M, Uz B, Kara A, Kilic MK, Halil M, Ulger Z, Yavuz BB, Haznedaroğlu IC et al. Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer’s disease (AD). Arch Gerontol Geriatr 2012; 55: 257–260.
Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer’s disease correlates with coated-platelet levels--a longitudinal study. Transl Res 2008; 152: 99–102.
Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettenati C, Mussi M, Parrinello G et al. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 2001; 57: 2243–2248.
Roselli F, Tartaglione B, Federico F, Lepore V, Defazio G, Livrea P. Rate of MMSE score change in Alzheimer’s disease: influence of education and vascular risk factors. Clin Neurol Neurosurg 2009; 111: 327–330.
Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66: 343–348.
Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 2002; 161: 433–439.
Forconi S, Wild P, Munzel T, Gori T. Endothelium and hyperviscosity. Clin Hemorheol Microcirc 2011; 49: 487–491.
Milionis HJ, Elisaf MS, Mikhailidis DP. Platelet function and lipid-lowering interventions. Platelets 1999; 10: 357–367.